Handelsinvest Investeringsforvaltning grew its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 32.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,000 shares of the company’s stock after purchasing an additional 14,700 shares during the quarter. Handelsinvest Investeringsforvaltning owned approximately 0.13% of Aerie Pharmaceuticals worth $2,850,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. Bank of Montreal Can raised its stake in Aerie Pharmaceuticals by 40.2% during the fourth quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock worth $38,000 after purchasing an additional 304 shares during the period. Pearl River Capital LLC purchased a new position in Aerie Pharmaceuticals during the fourth quarter worth approximately $59,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Aerie Pharmaceuticals by 23.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $99,000 after purchasing an additional 515 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in Aerie Pharmaceuticals during the fourth quarter worth approximately $105,000. Finally, Glenmede Trust Co. NA raised its stake in Aerie Pharmaceuticals by 46.1% during the third quarter. Glenmede Trust Co. NA now owns 5,663 shares of the company’s stock worth $348,000 after purchasing an additional 1,787 shares during the period.
Shares of AERI stock opened at $39.78 on Friday. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -8.55 and a beta of 0.83. Aerie Pharmaceuticals Inc has a 1-year low of $32.18 and a 1-year high of $74.75.
A number of research firms have weighed in on AERI. Mizuho reaffirmed a “buy” rating and set a $77.00 price target on shares of Aerie Pharmaceuticals in a research note on Sunday, April 21st. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 4th. Piper Jaffray Companies assumed coverage on shares of Aerie Pharmaceuticals in a research note on Thursday, March 21st. They issued an “overweight” rating and a $80.00 target price on the stock. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a report on Tuesday, March 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $76.50.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/handelsinvest-investeringsforvaltning-boosts-stake-in-aerie-pharmaceuticals-inc-aeri.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Article: Why is momentum important to successful trading?
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.